Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 87

Sort by

Sort Order Select

Journal Articles

Risk prediction for clonal cytopenia: multicenter real-world evidence

Blood (2024) 144 (19): 2033–2044.

https://doi.org/10.1182/blood.2024024756

Published: 2024

Includes: Supplemental data

Journal Articles

Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD

Blood (2024) 144 (9): 1010–1021.

https://doi.org/10.1182/blood.2024025106

Published: 2024

Includes: Supplemental data

Journal Articles

TMI-Based Dose-Escalated Bone Marrow Transplantation Can Help Preserve the Bone Marrow Microenvironment and Reduce Cellular Senescence in Old Mice

Ji Eun Lim, Srideshikan Sargur Madabushi, Hemendra Ghimire, Richardson Kimberly K, Paresh Vishwasrao, Amr M H Abdelhamid, Jeffrey Wong, Cynthia Aristei, Ha-Neui Kim, Daohong Zhou, Monzr M. Al Malki, Susanta Hui

Blood (2023) 142 (Supplement 1): 3424.

https://doi.org/10.1182/blood-2023-187062

Published: 2023

Journal Articles

Favorable Survival Outcomes in AML Patients Undergoing Allogeneic Hematopoietic Cell Transplant with Fludarabine/Melphalan-Conditioning with Tacrolimus/Sirolimus-Based Gvhd Prophylaxis

Blood (2023) 142 (Supplement 1): 4959.

https://doi.org/10.1182/blood-2023-187156

Published: 2023

Journal Articles

Initial Results of a Phase 1 Trial of TSC-100 and TSC-101, Engineered T Cell Therapies That Target Minor Histocompatibility Antigens to Prevent Relapse after Allogeneic Hematopoietic Cell Transplantation

Monzr M. Al Malki, Alla Keyzner, Hyung Chan Suh, Aasiya Matin, Erica Buonomo, Yun Wang, Nina Abelowitz, Jim Murray, Gavin Macbeath, Debora Barton, Shrikanta Chattopadhyay, Ran Reshef

Blood (2023) 142 (Supplement 1): 2090.

https://doi.org/10.1182/blood-2023-187355

Published: 2023

Journal Articles

A Phase 2, Single-Arm, Multicohort, Open Label, Multicenter Trial of Off-the-Shelf Natural Killer Cells (SAR445419) in Patients with High-Risk Myeloid Malignancies Undergoing Allogeneic HSCT

MHD Monzr M. Al Malki, Melhem M. Solh, Anurag K. Singh, Rushang D. Patel, Denis-Claude Roy, Agata Drewniak, Gu Mi, Lorraine Tracey, Giovanni Abbadessa, Richard E. Champlin

Blood (2023) 142 (Supplement 1): 4921.

https://doi.org/10.1182/blood-2023-173241

Published: 2023

Journal Articles

The Bone Marrow-Targeted Conditioning Stress Test Demonstrates Vertebrae Niche Being More Radio-Tolerant Than Femur, Indicating Skeleton Resilience and Global Heterogeneity

Srideshikan Sargur Madabushi, Ji Eun Lim, Hemendra Ghimire, Jeffrey Wong, Anthony Stein, Amandeep Salhotra, Monzr M. Al Malki, Susanta Hui

Blood (2023) 142 (Supplement 1): 5612.

https://doi.org/10.1182/blood-2023-190708

Published: 2023

Journal Articles

Improving Outcomes of Peripheral Blood Stem Cell (PBSC) HLA-Mismatched Unrelated Donor (MMUD) Hematopoietic Cell Transplantation (HCT): Effect of Graft Versus Host Disease (GVHD) Prophylaxis

Blood (2023) 142 (Supplement 1): 4896.

https://doi.org/10.1182/blood-2023-187909

Published: 2023

Journal Articles

Post-Transplant Cyclophosphamide Eliminates Disparity in GvHD-Free, Relapse-Free Survival and Overall Survival between 8/8 Matched and 7/8 Mismatched Unrelated Donor Hematopoietic Cell Transplantation in Adults with Hematologic Malignancies

Jeffery J. Auletta, Monzr M. Al Malki, Todd DeFor, Brian C. Shaffer, Mahasweta Gooptu, Javier Bolanos-Meade, Ramzi Abboud, Adrienne D. Briggs, Farhad Khimani, Dipenkumar Modi, Richard Newcomb, Elizabeth J. Shpall, Caitrin Bupp, Stephen R. Spellman, Heather E. Stefanski, Antonio M. Jimenez Jimenez, Steven M. Devine

Blood (2023) 142 (Supplement 1): 780.

https://doi.org/10.1182/blood-2023-172722

Published: 2023

Journal Articles

Patient-Reported Outcomes of BMT CTN 1703: A Randomized Phase III Study for Gvhd Prophylaxis - a Quality of Life Evaluation

Blood (2023) 142 (Supplement 1): 897.

https://doi.org/10.1182/blood-2023-187859

Published: 2023

Journal Articles

Total Marrow and Lymphoid Irradiation (TMLI) -Based Conditioning Regimen in Patients with Acute Leukemia Undergoing Allogeneic Hematopoietic Cell Transplant with Measurable Residual Disease

Blood (2023) 142 (Supplement 1): 2162.

https://doi.org/10.1182/blood-2023-185034

Published: 2023

Journal Articles

Consolidation with First and Second Allogeneic Transplants in Adults with Relapsed/Refractory B-ALL Following Response to CD19CAR T Cell Therapy

Blood (2023) 142 (Supplement 1): 4981.

https://doi.org/10.1182/blood-2023-182058

Published: 2023

Journal Articles

Outcomes of Patients Undergoing Fludarabine and Melphalan-Based Conditioning with Post-Transplant Cyclophosphamide for Peripheral Blood Stem Cell Allogeneic Hematopoietic Cell Transplant: Donor Type Effect

Blood (2023) 142 (Supplement 1): 2151.

https://doi.org/10.1182/blood-2023-187687

Published: 2023

Journal Articles

A Phase 1 Study of the Oral CDK9 Inhibitor Voruciclib in Relapsed/Refractory (R/R) B-Cell Lymphoma (NHL) or Acute Myeloid Leukemia (AML)

Matthew S Davids, Yesid Alvarado Valero, Catherine Diefenbach, Daniel N. Egan, Shira N. Dinner, Monzr M. Al Malki, Kebede Begna, Avyakta Kallam, Sameem Abedin, Rachel Cook, Nathalie Javidi-Sharifi, Edward Dominguez, Lu Miao, Richard G Ghalie, Alexey Danilov

Blood (2023) 142 (Supplement 1): 4286.

https://doi.org/10.1182/blood-2023-179577

Published: 2023

Journal Articles

Large-Scale Post-Transplant TCR Deep Sequencing Reveals a Major T Cell Diversity Bottleneck with Post-Transplant Cyclophosphamide with Implications for Both Efficacy and Toxicity: Results of the BMT CTN 1801 Study

Blood (2023) 142 (Supplement 1): 475.

https://doi.org/10.1182/blood-2023-188032

Published: 2023

Journal Articles

Combined Cytokine Blocking Therapy (CCBT) Using Basiliximab and Infliximab for Treatment of Steroid-Refractory Graft Versus Host Disease (SR-GvHD)

Blood (2023) 142 (Supplement 1): 4944.

https://doi.org/10.1182/blood-2023-190808

Published: 2023

Journal Articles

A Phase 1 Study of Venetoclax in Combination with a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed Adults with B-Cell Ph-like ALL

Blood (2023) 142 (Supplement 1): 2870.

https://doi.org/10.1182/blood-2023-187469

Published: 2023

Journal Articles

Real-Time Two-Photon Microscopy Reveals Spatially Heterogeneous T Lymphocyte Trafficking in the GI Microenvironment Influenced By GI Tissue Damage Level

Hemendra Ghimire, Srideshikan Sargur Madabushi, Ji Eun Lim, Guy Storme, Amandeep Salhotra, Loredana Ruggeri, Antonio Pierini, Monzr M. Al Malki, Susanta Hui

Blood (2023) 142 (Supplement 1): 2045.

https://doi.org/10.1182/blood-2023-187674

Published: 2023

Journal Articles

Fractionated Total Body Irradiation and Fludarabine Based Conditioning Regimen with Post-Transplant Cyclophosphamide (PTCy) for Mismatched Related and Unrelated Donors HCT for Acute Leukemia and MDS

Blood (2023) 142 (Supplement 1): 3537.

https://doi.org/10.1182/blood-2023-187728

Published: 2023

Journal Articles

Toxicities Associated with Tyrosine Kinase Inhibitor Maintenance Following Allogeneic Hematopoietic Cell Transplantation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Blood (2023) 142 (Supplement 1): 2873.

https://doi.org/10.1182/blood-2023-187460

Published: 2023

NARROW

Risk prediction for clonal cytopenia: multicenter real-world evidence

Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD

TMI-Based Dose-Escalated Bone Marrow Transplantation Can Help Preserve the Bone Marrow Microenvironment and Reduce Cellular Senescence in Old Mice

Favorable Survival Outcomes in AML Patients Undergoing Allogeneic Hematopoietic Cell Transplant with Fludarabine/Melphalan-Conditioning with Tacrolimus/Sirolimus-Based Gvhd Prophylaxis

Initial Results of a Phase 1 Trial of TSC-100 and TSC-101, Engineered T Cell Therapies That Target Minor Histocompatibility Antigens to Prevent Relapse after Allogeneic Hematopoietic Cell Transplantation

A Phase 2, Single-Arm, Multicohort, Open Label, Multicenter Trial of Off-the-Shelf Natural Killer Cells (SAR445419) in Patients with High-Risk Myeloid Malignancies Undergoing Allogeneic HSCT

The Bone Marrow-Targeted Conditioning Stress Test Demonstrates Vertebrae Niche Being More Radio-Tolerant Than Femur, Indicating Skeleton Resilience and Global Heterogeneity

Improving Outcomes of Peripheral Blood Stem Cell (PBSC) HLA-Mismatched Unrelated Donor (MMUD) Hematopoietic Cell Transplantation (HCT): Effect of Graft Versus Host Disease (GVHD) Prophylaxis

Post-Transplant Cyclophosphamide Eliminates Disparity in GvHD-Free, Relapse-Free Survival and Overall Survival between 8/8 Matched and 7/8 Mismatched Unrelated Donor Hematopoietic Cell Transplantation in Adults with Hematologic Malignancies

Patient-Reported Outcomes of BMT CTN 1703: A Randomized Phase III Study for Gvhd Prophylaxis - a Quality of Life Evaluation

Total Marrow and Lymphoid Irradiation (TMLI) -Based Conditioning Regimen in Patients with Acute Leukemia Undergoing Allogeneic Hematopoietic Cell Transplant with Measurable Residual Disease

Consolidation with First and Second Allogeneic Transplants in Adults with Relapsed/Refractory B-ALL Following Response to CD19CAR T Cell Therapy

Outcomes of Patients Undergoing Fludarabine and Melphalan-Based Conditioning with Post-Transplant Cyclophosphamide for Peripheral Blood Stem Cell Allogeneic Hematopoietic Cell Transplant: Donor Type Effect

A Phase 1 Study of the Oral CDK9 Inhibitor Voruciclib in Relapsed/Refractory (R/R) B-Cell Lymphoma (NHL) or Acute Myeloid Leukemia (AML)

Large-Scale Post-Transplant TCR Deep Sequencing Reveals a Major T Cell Diversity Bottleneck with Post-Transplant Cyclophosphamide with Implications for Both Efficacy and Toxicity: Results of the BMT CTN 1801 Study

Combined Cytokine Blocking Therapy (CCBT) Using Basiliximab and Infliximab for Treatment of Steroid-Refractory Graft Versus Host Disease (SR-GvHD)

A Phase 1 Study of Venetoclax in Combination with a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed Adults with B-Cell Ph-like ALL

Real-Time Two-Photon Microscopy Reveals Spatially Heterogeneous T Lymphocyte Trafficking in the GI Microenvironment Influenced By GI Tissue Damage Level

Fractionated Total Body Irradiation and Fludarabine Based Conditioning Regimen with Post-Transplant Cyclophosphamide (PTCy) for Mismatched Related and Unrelated Donors HCT for Acute Leukemia and MDS

Toxicities Associated with Tyrosine Kinase Inhibitor Maintenance Following Allogeneic Hematopoietic Cell Transplantation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only